The aim of this study was to identify the risk factors for acute graft-versus-host disease (aGVHD) in children transplanted from a matched-sibling donor (MSD) or an unrelated donor (UD). In all, 87 children consecutively underwent allogeneic bone marrow transplantation (BMT) from MSD (n ¼ 36), and UD (n ¼ 51). GVHD prophylaxis included CsA alone (n ¼ 33) or with MTX (n ¼ 51). ATG was added in UD-BMT and thalassemic recipients. CsA whole-blood concentrations were measured by EMIT and the dosing regimen was monitored by Bayesian pharmacokinetic modelling. Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II-IV aGVHD than those developing no GVHD or only grade I (5779 vs 9478 ng/ml, P ¼ 0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups. TBC o85 ng/ml and 'use of MTX' were associated with aGVHD in MSD-SCT (P ¼ 0.003 and 0.007, respectively) as well as in UD-SCT (P ¼ 0.006 and 0.003). Donor age X8 years was significant only in MSD-BMT. Our results have shown the significant decisive role of pharmacological factors such as CSA TBC or use of MTX in the occurrence of GVHD in MSD as well as in UD paediatric BMT. Bone Marrow Transplantation (2003) 32, 881-887. doi:10.1038/sj.bmt.1704239 Keywords: acute GVHD; risk factor; cyclosporine; paediatrics Allogeneic bone marrow transplantation (BMT) is curative in a number of malignant haematological diseases, aplastic anaemia, inborn errors of metabolism and immunodeficiencies. Despite progress in prophylaxis, acute graft-versus-host disease (aGVHD) continues to account for significant morbidity and mortality in children transplanted from matched-sibling donors (MSD) 1,2 or unrelated donors (UD).
paediatrics Allogeneic bone marrow transplantation (BMT) is curative in a number of malignant haematological diseases, aplastic anaemia, inborn errors of metabolism and immunodeficiencies. Despite progress in prophylaxis, acute graft-versus-host disease (aGVHD) continues to account for significant morbidity and mortality in children transplanted from matched-sibling donors (MSD) 1, 2 or unrelated donors (UD). [3] [4] [5] [6] Moreover, aGVHD is a major risk factor for the occurrence of chronic GVHD in paediatric BMT. 7 Several studies have shown that mild aGVHD is associated with a decreased risk of relapse in allogeneic MSD-BMT [8] [9] [10] [11] [12] [13] and has a positive impact on leukaemia-free survival in chronic and acute leukaemia. However, severe aGVHD is associated with unacceptable transplantation-related mortality and should be avoided. [11] [12] [13] Numerous clinical risk factors for aGVHD have previously been identified on cohorts including both adults and children. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Moreover, monotherapy with CsA or MTX vs CsA associated to MTX [26] [27] [28] [29] and a low trough blood concentration of CsA (CsA TBC) during the early post transplantation period [30] [31] [32] were recognized as major risk factors for aGVHD. Unfortunately, these studies essentially focused on adults and only one study conducted in children was available. 33 However, prophylaxis against GVHD used in this study was MTX alone and results could not be transposed to children receiving CsA alone or in association with other drugs. Moreover, most of the previous studies were conducted in MSD-BMT only, and the relevance of the risk factors for aGVHD found in MSD-BMT has to be clarified for UD-BMT.
To improve GVHD prophylaxis in paediatric BMT, we aimed to determine the definitive risk factors for aGVHD in children transplanted from an MSD or UD and receiving CsA alone or with MTX and/or in vivo T-cell depletion.
Patients and methods

Patients and donors
From October 1997 to October 2001, 87 children (54 male and 33 female) aged 3 months up to 18 years consecutively underwent allogeneic BMT in Debrousse Hospital (Lyon, France). Indications for transplantation were: malignant haemopathies (n ¼ 48), nonmalignant haemopathies (n ¼ 17), inborn errors of metabolism (n ¼ 13), immunodeficiencies (n ¼ 6) and others (n ¼ 3). In all, 36 children received BMT from an MSD. A total of 51 children were transplanted from an UD: 20 were matched for the loci A, B and DR, 31 were mismatched at 1-3 loci. Stem cell source was unmanipulated bone marrow for all donors. Methods used for HLA typing in patients and donors are described in detail by Souillet et al. 34 Patient and donor characteristics are described in Table 1 .
Conditioning regimen
Pretransplant conditioning consisted of TBI with etoposide in 19 patients or other drugs in 11 patients. Other patients were conditioned with cytotoxic drugs alone: busulphan with cyclophosphamide (CY) in 39 patients or with other drug(s) in nine patients. CY was used alone in nine patients.
GVHD prophylaxis
In MSD-SCT, prophylaxis usually included CsA alone (n ¼ 9) or with a short course of MTX (n ¼ 16). Patients transplanted for thalassemia received CsA with antithymocyte globulin (ATG) (Thymoglobuline s , Imtix Sangstat, Lyon, France) (n ¼ 6). ATG was given prior to transplantation (total dose between 10 and 20 mg/kg) to obtain partial in vivo T-cell depletion. No GVHD prophylaxis was administered to three patients receiving a second MSD-SCT. Two patients received CsA with MTX and ATG. In UD-SCT, prophylaxis included ATG with MTX and CsA (n ¼ 33). The use of MTX was stopped after October 2000, and subsequent prophylaxis included only CsA þ ATG (n ¼ 18). None of the 87 patients were in vitro T-cell depleted. For most indications, CsA was initiated intravenously as an 8 h infusion (initial dose: 5 mg/kg/day starting on the day preceding the transplant, except for ALL: 3 mg/kg/day). When oral medication could be tolerated, CsA was administered orally every 12 h at a dose calculated for each patient. The median day of conversion from intravenous to oral cyclosporine was day 14. Duration of CsA therapy was 3 months in ALL, 6 months in other malignant diseases and 9 months in nonmalignant diseases. It was extended by 3 months when aGVHD was diagnosed. MTX (15 mg/m 2 ) was administered intravenously on day 1 and 10 mg/m 2 on days 3, 6 and 11 (except for Fanconi anaemia: only three doses). When gut toxicity occurred, only three doses of MTX were administered.
CsA assay on whole blood
Measurements of cyclosporine blood concentrations were performed by immunoenzymatic assay (EMIT on Cobas MIRA analyser, Behring Diagnostic, France). The limit of detection was 30 ng/ml. The analytical error assay pattern could be described by the following relationship: s.d. ¼ 0.001460 þ 0.034560 Â C (where s.d. is the standard deviation of the measurement and C the measured concentration). During intravenous treatment, the CsA blood concentration was measured twice weekly from day þ 1 after transplantation, using peripheral venous blood samples. After the switch IV-oral, the CsA blood concentration was measured twice weekly during the first month post transplantation, using central venous samples (except during the first 3 days after the switch, when peripheral venous samples were used).
Individualization of the CsA regimen
A patient file was made for each patient beginning CsA therapy, by using the file manager program (PASTRX) included in the USC*PACK software. 35 Each file contained anthropometric and treatment data such as age, weight, administered amounts of CsA, time of administration, infusion duration, blood sampling times and drug blood level measurements. The individual pharmacokinetic parameter values were then estimated for a two-compartment model, using a maximum a posteriori (MAP) Bayesian method also implemented in USC*PACK. 36 This method Clinical and pharmacological risk factors for aGVHD P Martin et al allows accurate estimation of the whole drug blood concentration vs time profile from only one to three drug blood level measurements, by combining the available patient information (PASTRX file) and population information (the distribution of pharmacokinetic parameter values had been obtained from similar patients previously treated). Moreover, the analytical error was taken into account for the determination of pharmacokinetic parameters, as each measured drug concentration was weighted by the reciprocal of its variance associated with the assay error equation described above. This permits one to attribute a credibility level to each measured blood concentration, increasing the accuracy of the estimates. 37 The individual pharmacokinetic parameter values were then used to simulate future CsA blood concentrations and to determine consequently the doses necessary to reach target CsA blood concentrations at any time. As no precise data on efficient blood concentrations were available on this population, the choice of target values was based on our experience.
Risk factors for aGVHD
Pharmacological and clinical risk factors were studied. Pharmacological factors included qualitative factors: 'immunosuppression with CsA alone' vs 'CsA and MTX', ATG, and quantitative factors, focused on CsA exposure: peak blood concentration (PBC), TBC and area under the concentration curve (AUC) vs time. Monitoring of CsA was aimed at reaching a desired TBC, whatever was the dose required to reach it. However, not all patients achieved the desired CsA TBC and the final doses of CsA administered were very variable from patient to patient, and also in the same patient from one day to another (between 1 and 8 mg/kg/day). This is why only the blood concentration was tested as a risk factor for aGVHD and not the dose of CsA. Mean PBC, TBC and AUC were retrospectively estimated for each patient by the MAP Bayesian modelling procedure, for the first 2 weeks after transplantation and compared with Mann-Whitney rank-sum test vs no or grade I aGVHD between children who developed grade II-IV aGVHD. Clinical risk factors that might have influenced the development of aGVHD were: recipient age, recipient sex, donor age, donor sex, female donor to male recipient vs other combinations, sex match vs sex mismatch. TBC, 'immunosuppression with CsA alone vs CsA and MTX', ATG and clinical risk factors were studied by univariate analysis using Pearson's w 2 tests. Significant factors (Po0.05) found by univariate analysis were included in a stepwise logistic regression multivariate analysis. Univariate and multivariate analyses were conducted in each subgroup (MSD-and UD-BMT) and in whole cohort. Matched (n ¼ 20) and mismatched (n ¼ 31) UD-BMT were combined in univariate and multivariate analyses because a similar incidence of aGVHD was observed between these two subgroups (data not shown). Grade II-IV aGVHD was regarded as the event. Cumulative probabilities of grade II-IV acute GVHD were calculated by the Kaplan-Meier method. In all, 20 and 74 patients had, respectively, grade II-IV aGVHD or survival of at least 25 days without aGVHD (or only grade I). All patients were included in the analysis.
Grading of aGVHD
aGVHD was graded according to Glucksberg et al. 38 Skin or gastrointestinal biopsies were always performed to confirm Glucksberg grading. Liver biopsy was performed only when the patient's clinical status allowed it. In the other cases, other causes of liver impairment were carefully eliminated.
Statistical analysis
All statistical analyses were performed by using SPSS for Windows (version 9.0. SPSS, Chicago, IL, USA).
Results
Incidence of acute GVHD
Acute GVHD developed in 46.0% of the whole cohort: grade I: 26. 4% (n ¼ 23); grade II: 10.3% (n ¼ 9); grade III: 4.6% (n ¼ 4); grade IV: 4.6% (n ¼ 4). Cumulative probabilities of developing aGVHD were: all grades: 46% (42-54%), grades II-IV: 20% (16-24%), grades III-IV: 9% (6-12%).
The incidence of aGVHD was 44.4% in MSD-SCT: grade I: 19.4% (n ¼ 7); grade II: 11.1% (n ¼ 4); grade III: 2.8% (n ¼ 1); grade IV: 11.1% (n ¼ 4). Cumulative probabilities in this subgroup were: all grades: 44% (36-53%); grades II-IV: 25% (18-32%); grades III-IV: 14% (8-20%). Five patients suffered severe aGVHD in the MSD-SCT subgroup. The incidence of aGVHD was 47.0% in UD-SCT): grade I: 31.4% (n ¼ 16); grade II: 9.8% (n ¼ 5); grade III: 5.9% (n ¼ 3). Cumulative probabilities in UD-BMT were: all grades: 47% (40-55%); grades II-IV: 16% (10-21%); grades III-IV: 6% (3-9%). Only three cases of severe aGVHD occurred in this subgroup. Table 2 gives details about the incidence of GVHD in malignant and nonmalignant diseases.
Mean TBC, PBC and AUC and occurrence of grade II-IV aGVHD
As shown in Table 3 , the mean CsA TBC during the first 2 weeks after transplantation was lower in patients who had developed grade II-IV aGVHD than in those having Table 2 Incidence of aGVHD in MSD-and UD-BMT
Disease Donor
Matched sibling Unrelated Clinical and pharmacological risk factors for aGVHD P Martin et al no or only grade I aGVHD (P ¼ 0.007). On the other hand, the PBC and AUC were similar between both groups. The incidence of aGVHD was not associated with a low PBC or low AUC of CsA. Therefore, TBC was the only pharmacokinetic risk factor included in the subsequent univariate analysis.
Univariate analysis
Only two factors were significantly associated with grade II-IV aGVHD in MSD-BMT and UD-BMT: prophylaxis with CsA alone (or no prophylaxis) vs the combination of MTX and CsA (P ¼ 0.007 and 0.003, respectively) and mean CsA TBC o85 ng/ml (P ¼ 0.003 and 0.006, respectively), as shown in Table 4 . Donor age X8 years was recognized as a risk factor for aGVHD in MSD-BMT (P ¼ 0.014) but not in UD-BMT (P ¼ 0.366). Other clinical risk factors that were not significantly associated with aGVHD included recipient sex, recipient age, donor sex, female donor to male recipient vs other combinations and patient/donor sex match vs sex mismatch. Donor type and use of ATG were not significantly associated with the occurrence of aGVHD in the whole cohort. Unfortunately, the influence of ATG could not be tested in each subgroup because it was used in all UD-BMT but in only a few MSD-BMT. Table 3 Mean values of pharmacokinetic index for the first 2 weeks after transplantation according to the occurrence of grade II-IV aGVHD (n ¼ 87)
Pharmacokinetic index
Grade II-IV aGVHD (n ¼ 17) Table 5 shows factors identified on univariate analysis that independently predicted aGVHD. In MSD-BMT, CsA TBC o85 ng/ml (P ¼ 0.010), 'use of short courses of MTX' and donor age p8 years (P ¼ 0.006) independently predicted aGVHD, although statistical significance was not achieved for MTX (P ¼ 0.094). Likewise, in UD-BMT, factors highlighted on univariate analysis in this subgroup could independently predict the occurrence of aGVHD: CsA TBC o85 ng/ml (P ¼ 0.003) and 'use of short courses of MTX' (P ¼ 0.011).
Multivariate analysis
Discussion
Although the degree of HLA disparity between patient and donor was recognized as a major risk factor for aGVHD, [39] [40] we found a similar aGVHD incidence in MSD-BMT and UD-BMT. Moreover, donor type was not recognized as a risk factor for aGVHD in the whole cohort. However, patients transplanted with UD-BMT received a more intensive immunosuppressive regimen than patients transplanted receiving MSD-BMT. The similar aGVHD incidence between the two groups could be explained by the intensive immunosuppressive regimen used in UD-BMT, including in vivo T-cell depletion.
Among different CsA pharmacokinetic risk factors for aGVHD studied, only the mean TBC differed between patients having developed grade II-IV aGVHD and those having developed no or mild aGVHD. In contrast with results found in renal transplantation, 41 we did not find any relationship between AUC and CsA efficiency in paediatric SCT. This could be explained by a possible time-dependent action of CsA (as has been described for vancomycin for example) in the special case of bone marrow transplantation. Indeed, the use of CsA is intented to prevent the reaction of the graft against the recipient, in contrast to solid organ transplantation where CsA prevents the recipient attacking the graft. If the immunosuppressive effect can be facilitated by adequate inhibition of the aggressor, we can suppose that CsA distributes more easily in bone marrow than in the deep tissues in the case of solid organ transplants, which require a greater gradient of CsA concentration, achieved with higher CsA blood peak levels and consequently a higher AUC.
Our results clearly show that low CsA TBC during the early post transplant period and the use of short courses of MTX can be considered as major risk factors for acute GVHD in paediatrics, in MSD-BMT as well as in UD-BMT. In contrast to previous studies, we could not find any clinical risk factor for aGVHD, except donor age that was significant only in MSD-BMT. Our results seem disappointing in so far as four clinical risk factors for aGVHD were found by Eisner et al 33 33 but donor sex was not significant in our cohort.
Owing to the numerous risk factors for aGVHD recognized in studies conducted over the past 25 years, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] we can surmize that the number of patients included in our study was too small to determine accurately the factors likely to influence the incidence of aGVHD. Moreover, the two subgroups presented in this paper are very different concerning the donor type and GVHD prophylaxis and they could not be pooled. In agreement with a previous study, our results suggest that donor age is the main clinical risk factor for aGVHD in paediatric BMT. Nevertheless, these results suggest that pharmacological risk factors such as CsA TBC and use of MTX are more important for aGVHD occurrence than clinical risk factors such as recipient/donor age and sex.
Despite our negative results concerning the clinical risk factors for aGVHD -with the exception of donor age in MSD-BMT-the influence of some factors in paediatric BMT can be discussed. Age and sex of donor and/or recipient as risk factors for aGVHD have been identified in numerous studies. Several teams previously found female donor sex to be a risk factor for aGVHD. 15, 18, 21 According to other authors, female donor sex was significant only if the recipient was male. 14, 16, 22 If donor age was recognized as a risk factor, 17, 25, 26 this risk could be restricted to female sex donors. 21 Risk factors found by Gale et al 22 were: patient/donor sex mismatch, if the donor was female (immunized by previous pregnancy and/or transfusions, or not immunized), and patient age. However, patient age was not significant when an immune female donor into a male recipient was excluded. Nash et al 26 have found several risk factors such as patient age, donor age and patient/donor sex mismatch. However, these factors were not significant on multivariate analysis, with the exception of patient/donor sex mismatch, and only if the donor was female and immunized. These studies 15, 21, 22, 26 suggest that donor and/or recipient age and donor and/or recipient sex are significant clinical risk factors for aGVHD, essentially when the cohort includes female immunized donors.
In contrast to previous studies conducted in adults, our subgroup of MSD-BMT included no immunized female donors (data not shown). Clinical and pharmacological risk factors for aGVHD P Martin et al
As previously shown by Eisner et al, 33 donor age was a significant risk factor for aGVHD in our paediatric cohort, although this subgroup included no immunized female donors. Although our subgroup of UD-BMT included some immunized female donors, no clinical risk factors for aGVHD were found. We can surmize that the intensive immunosuppressive regimen used in UD-SCT could, at least partially, suppress the influence of other risk factors.
In this study, any influence of clinical risk factors on the occurrence of acute GVHD has not been found significantly, with the exception of donor age at MSD-BMT. Finally, our results revealed the definitive role of pharmacological factors such as CsA TBC in the occurrence of aGVHD in MSD-as well as in UD-paediatric BMT.
